⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ENTX News
Entera Bio Ltd. Ordinary Shares
Parent Project Muscular Dystrophy Hosts 2026 Annual Conference in Orlando, Florida
prnewswire.com
CAPR
SRPT
CATX
BMRA
EDSA
ENTX
SLDB
WVE
Positive FDA Feedback on Phase 3 Brings Entera Bio's Oral Osteoporosis Pill One Step Closer to Market
globenewswire.com
ENTX
Entera Bio Receives Positive FDA Feedback on 12-Month Registrational Phase 3 Study for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosis
globenewswire.com
ENTX
Entera Reports Robust Preclinical Data for EB612 (Oral LA-PTH(1-34)) for Hypoparathyroidism and EB618 (Oral GLP-1/Glucagon) for Obesity at ENDO 2026
globenewswire.com
ENTX
OPK
ENDO 2026 Oral Presentation Highlights Comparative Clinical Data for Entera’s Breakthrough Single Tablet EB613 (First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis)
globenewswire.com
ENTX
Entera’s EB613, First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis - Single Tablet Data Selected for Late Breaking Oral Presentation at ENDO 2026 Annual Meeting; Additional Oral Peptide Pipeline Data Accepted for Presentation
globenewswire.com
ENTX
Form 8-K
sec.gov
ENTXW
ENTX
Entera Announces First Quarter 2026 Financial Results and Updates Across its Oral Peptide Programs
globenewswire.com
ENTX
BriefCast Publishes Transcript: Entera Bio's Osteoporosis KOL Roundtable on EB613 - Oral Anabolic Tablet Opportunity
globenewswire.com
ENTX
Entera Bio to Host Key Opinion Leader Webinar Highlighting the Osteoporosis Treatment Landscape and the Opportunity for EB613
globenewswire.com
ENTX